Chimeric Therapeutics Ltd has released a press release.
AML patient achieves Complete Response in CHM CORE-NK trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Appendix 4E and Preliminary Final Report
- First patient dosed in Phase 1/2 trial of CHM CDH17
- First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
- Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
- Chimeric opens CHM CDH17 Phase 1/2 trial
Later from Chimeric Therapeutics
- $5 million Placement to progress CHM CDH17 trial
- Reinstatement to Official Quotation
- AGM Presentation and CEO Appointment
- Chimeric receives $4.17m R&D tax incentive
- Phase 1B CHM CORE-NK trial advances to newly diagnosed AML
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics